Global Pharma Companies Begin Conducting Comparative Effectiveness Research During Phase 3 of Product Development RESEARCH TRIANGLE PARK, NC--(Marketwired - June 26, 2017) - Research from global market access teams found that pharmaceutical and medical device companies often wait until Phase 3 or later to...

Global Pharmaceutical Comparative Effectiveness Research Teams Increasing Budgets RESEARCH TRIANGLE PARK, NC--(Marketwired - July 21, 2016) - Pharmaceutical companies' comparative effectiveness (CER) managers indicate upward trends in spending from an average $5 million budget,...

Drug Companies Spend an Average $13,000 per Patient on Comparative Effectiveness Research in Phase IV RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 9, 2011) - The cost of running a comparative effectiveness trial is $13,087 per patient during Phase IV, according to a study by Cutting Edge...